Literature DB >> 1106845

Clinical trial of the oral form of a new podophyllotoxin derivative, VP-16-213 (NSC-141540), in patients with advanced neoplastic disease.

N I Nissen, H H Hansen, H Pedersen, I Stroyer, P Dombernowsky, M Hessellund.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1975        PMID： 1106845

Source DB:  PubMed          Journal:  Cancer Chemother Rep        ISSN： 0069-0112


× No keyword cloud information.
  10 in total

Review 1.  The clinical pharmacology of VM26 and VP16-213. A brief overview.

Authors:  P J Creaven
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

2.  A new iridoid glycoside and NO production inhibitory activity of compounds isolated from Russelia equisetiformis.

Authors:  Madoka Ochi; Katsuyoshi Matsunami; Hideaki Otsuka; Yoshio Takeda
Journal:  J Nat Med       Date:  2011-08-06       Impact factor: 2.343

Review 3.  Etoposide and teniposide. Bioanalysis, metabolism and clinical pharmacokinetics.

Authors:  J J Holthuis
Journal:  Pharm Weekbl Sci       Date:  1988-06-17

4.  The effect of dose on the bioavailability of oral etoposide.

Authors:  V J Harvey; M L Slevin; S P Joel; A Johnston; P F Wrigley
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

5.  Constituents of cultivated Agaricus blazei.

Authors:  Yumi Ueguchi; Katsuyoshi Matsunami; Hideaki Otsuka; Kazunari Kondo
Journal:  J Nat Med       Date:  2011-01-18       Impact factor: 2.343

Review 6.  Current development of podophyllotoxins.

Authors:  R Canetta; P Hilgard; S Florentine; P Bedogni; L Lenaz
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

7.  Rearranged ent-kauranes from the stems of Tricalysia dubia and their biological activities.

Authors:  Naoko Tamaki; Katsuyoshi Matsunami; Hideaki Otsuka; Takakazu Shinzato; Mitsunori Aramoto; Yoshio Takeda
Journal:  J Nat Med       Date:  2008-04-15       Impact factor: 2.343

Review 8.  Podophyllotoxin derivative VP 16-213.

Authors:  A M Arnold
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

Review 9.  The clinical pharmacology of etoposide and teniposide.

Authors:  P I Clark; M L Slevin
Journal:  Clin Pharmacokinet       Date:  1987-04       Impact factor: 6.447

10.  [Etoposide VP 16--213)--a podophyllotoxinderivative with high antitumor activity (author's transl)].

Authors:  H J Schmoll; N Niederle; W Achterrath
Journal:  Klin Wochenschr       Date:  1981-11-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.